Hepatocellular Carcinoma Surveillance Strategies: Major Guidelines and Screening Advances.

Autor: Wu G; Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA., Bajestani N; Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA., Pracha N; Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA., Chen C; Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA., Makary MS; Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2024 Nov 24; Vol. 16 (23). Date of Electronic Publication: 2024 Nov 24.
DOI: 10.3390/cancers16233933
Abstrakt: Background/objectives: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, with prognosis and treatment outcomes that are significantly influenced by the stage at diagnosis. Early detection through regular surveillance is crucial for improving patient outcomes, especially in high-risk groups such as those with cirrhosis or chronic hepatitis B. Geographic variations in HCC risk factors, including viral hepatitis and non-alcoholic fatty liver disease (NAFLD), have led to the development of different international surveillance guidelines. This review aims to compare and evaluate the surveillance strategies proposed by the Asian Pacific Association for the Study of the Liver (APASL), the American Association for the Study of Liver Diseases (AASLD), and the European Association for the Study of the Liver and European Organization for Research and Treatment of Cancer (EASL-EORTC).
Methods: The review examined and compared major international guidelines on HCC surveillance, focusing on patient selection, imaging modalities, and the integration of biomarkers. We also explored recent advancements in screening techniques, including artificial intelligence and emerging biomarkers, to identify future directions for improving surveillance strategies.
Results: Our analysis identified key differences in the guidelines, particularly in imaging modality preferences and the use of biomarkers for early detection. While all guidelines place emphasis on high-risk populations, the inclusion criteria and surveillance intervals vary. Additionally, novel technologies such as artificial intelligence show potential to enhance the accuracy and efficiency of HCC detection.
Conclusions: This review highlights the need to harmonize the international guidelines, particularly in regard to patients with non-cirrhotic NAFLD who remain under-represented in current surveillance protocols. Future research should focus on integrating emerging technologies and biomarkers to improve early detection and overall patient outcomes.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje